Pleth Variability Index for Predicting Low Blood Pressure During Maintenance Hemodialysis

Launched by FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE · Jun 7, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether a tool called the Pleth Variability Index (PVI) can help predict low blood pressure during routine hemodialysis treatments. Low blood pressure can be a common and serious issue for patients undergoing dialysis, so the study aims to see if monitoring PVI, which is a simple measurement taken from a fingertip device, can give healthcare providers early warning signs to help keep patients safe during their sessions.

To participate in this study, you need to be an adult between the ages of 18 and 80 who has been receiving regular hemodialysis for more than three months. During the study, your PVI will be measured before and about half an hour into your dialysis session, and your blood pressure will be closely monitored throughout. While the study poses no extra risks beyond your normal treatment, it offers a chance to improve the safety and comfort of dialysis for everyone in the future. Participation is completely voluntary, and you can withdraw at any time without affecting your medical care. Your privacy will be well protected throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18 to 80 years.
• • Diagnosis of end-stage renal disease and undergoing maintenance hemodialysis for more than 3 months.
• • Able and willing to provide informed consent and comply with study procedures.
• Exclusion Criteria:
• • Severe cardiac arrhythmias or significant peripheral vascular disease that may interfere with PVI measurements.
• • Local edema, skin lesions, or other conditions that prevent accurate PVI monitoring.
• • History of hemodynamic instability unrelated to dialysis.
• • Pregnant or breastfeeding women.
• • Known allergy or contraindication to materials used in the hemodialysis circuit.
• • Unable to cooperate with study procedures.
• • Participation in another interventional clinical study within the past 30 days.